The cannabis sector has been on fire recently. Since Nov. 2, the Horizons Marijuana Life Sciences ETF — an industry benchmark — is up by 105.6%, compared to gains of 18.9% for the S&P 500 index in the same period. Recent developments in the U.S. have helped spur this bull run for pot companies, with several states voting during the November elections to make recreational and/or medical marijuana legal.
Further, the Democratic Party, which tends to have a more friendly attitude toward cannabis, now controls all three branches of the U.S. government. Thanks to these tailwinds, the future of the cannabis industry looks increasingly promising, and there are plenty of excellent marijuana stocks to consider purchasing. But there are also companies investors would do well to avoid. Two pot growers firmly on the latter list are Cronos Group (NASDAQ:CRON) and Sundial Growers (NASDAQ:SNDL).
Here’s why neither of these stocks is worth your hard-earned money.
1. Cronos Group
Cronos Group has sometimes been touted as one of the most promising cannabis companies around. Perhaps the main reason behind investors’ enthusiasm is the pot grower’s partnership with Altria. As a reminder, the tobacco giant acquired a 45% stake in Cronos Group for $2.4 billion Canadian dollars in a transaction that closed in March 2019.
Cannabis companies have struggled to find nondilutive ways to raise capital, and for that reason, Cronos’s agreement with Altria was a big deal. Unfortunately, the marijuana player has constantly recorded mixed (if not downright disappointing) financial results, and the fourth quarter of 2020, which ended Dec. 31, was no different.
The company did report revenue of CA$17 million during the quarter, representing a 133% year-over-year jump. But that metric is a lot less impressive than it seems at first. For one, Cronos’ actual revenue numbers are much smaller than those of many of its biggest competitors in the Canadian cannabis market. For reference, Aphria‘s revenue during its comparable period was CA$160.5 million, up 33% year over year. It is much easier for the company with significantly smaller sales to increase its top line by triple-digit percentages.
What’s more, Aphria and Canopy Growth are currently fighting for the top market share in the Canadian cannabis market. While Cronos does generate the bulk of its revenue from its domestic operations, it lags behind its competitors in terms of revenue and market share.
And while Cronos has its eyes set on the U.S. market as well, the company’s revenue in the U.S. during the fourth quarter was just $3.5 million. This did mark a 30% year-over-year increase, but there are much bigger players than Cronos in the U.S. market, too.
Cronos’s net loss of $61.1 million during the quarter was a big drop from net income of $89.8 million in the year-ago period. It would be easier to ignore the red ink on the bottom line if Cronos’s revenue and market share compared favorably to that of its peers, and it would be easier to ignore all of these issues if Cronos boasted a more attractive valuation than its peers — but even that is not the case, as the graph below shows.
CRON PS Ratio data by YCharts
While Cronos may end up turning things around, for now it is difficult to justify investing in this cannabis stock as opposed to others with stronger operations, more impressive financial results, and more attractive valuations.
2. Sundial Growers
Penny stocks are worth little more than pocket change for a reason: The market doesn’t see them as great long-term bets. Of course, that alone doesn’t mean all penny stocks are to be avoided, but as a general rule, it is best to proceed with extreme caution when investing in these companies. That brings us to Sundial Growers, a penny stock that has been generating quite the buzz in recent weeks, with its share price skyrocketing earlier this year thanks to traders from Reddit’s r/WallStreetBets who took an interest in the cannabis company.
But there doesn’t seem to be much in the way way of fundamentals to back up Sundial Growers’ recent run. Here are just two of the many reasons to stay away from the hype. First, the company continues to record steep net losses. During fiscal 2020, which ended Dec. 31, Sundial Growers recorded a net loss of CA$239.9 million (admittedly an improvement over the net loss of CA$271.6 it saw during fiscal 2019).
Sundial’s revenue also dropped to CA$60.9 million in 2020, down from CA$63.6 million during the previous fiscal year. The company is in the process of, as CEO Zach George put it, “repositioning” its cultivation practices. To what end? According to management, the Canadian cannabis market is evolving, and shifting consumer preferences are part of this evolution. Consumers are currently more likely to purchase high-potency cannabis products, for instance.Sundial Growers is looking to better meet consumers’ needs with its repositioning efforts.
However, the marijuana company has a long way to go before it can show that these efforts will yield strong and growing revenue quarter after quarter. And even if it does, here is reason No. 2 to stay away: Sundial Growers is making it a habit to resort to dilutive forms of financing. In August 2020, the company conducted a $20 million registered offering.
Since then, Sundial Growers has gone through several more dilutive rounds of financing, including a $100 million offering in January. The combination of mediocre financial results, share dilution galore, and highly volatile stock price movements that are largely unrelated to business fundamentals hardly adds up to a company any long-term-oriented investor should even consider buying.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.